Pharma BD Deal Intelligence
Sanofi-Aventis / BiPar Sciences, Inc.
2009 · Acquisition/Merger · $500M · Complete
Announcement Sentiment
29
Negative
Sanofi-aventis agreed to acquire BiPar Sciences for up to $500M, contingent on milestones, to gain the PARP inhibitor BSI-201 (iniparib) in oncology.
Key facts
- Announced Apr 15, 2009
- Deal value $500M
- Deal type Acquisition/Merger
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals